The IBC is comprised of multiple individuals with various backgrounds to ensure the necessary expertise needed for properly and effectively reviewing all protocol submissions appropriately. Per the NIH Guidelines, the IBC membership must consist of the following:
"The Institutional Biosafety Committee must be comprised of no fewer than five members so selected that they collectively have experience and expertise in recombinant or synthetic nucleic acid molecule technology and the capability to assess the safety of recombinant or synthetic nucleic acid molecule research and to identify any potential risk to public health or the environment. At least two members shall not be affiliated with the institution (apart from their membership on the Institutional Biosafety Committee) and who represent the interest of the surrounding community with respect to health and protection of the environment".
The IBC roster is continually updated as committee members join and exit. The roster is maintained with the Office of Biotechnology Activities (OBA) within the NIH and is also found here.